Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-11-15 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Morepen Laboratories Ltd has informed BSE regarding issuance of Duplicate Share Certificates by the Company.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references Regulation 39(3) of the SEBI Listing Obligations and Disclosure Requirements, 2015, which pertains to share certificate management. The content is about a corporate action related to share certificates, specifically the issuance of duplicates, and includes details of the certificates and shareholders involved. This is not a financial report, earnings release, or management discussion. It is a regulatory announcement about share certificate issuance, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) or Director's Dealing (DIRS). The document length is short and it is an official communication to exchanges, not a report or presentation.
2019-11-15 English
Investors Presentation (Q2'FY20), November, 2019, based on the financial performance of the Company for the Quarter and Half-year ended 30th September, 2019.
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation (Q2'FY20), November, 2019' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter and half-year ended 30th September 2019, including revenue, profit, segment-wise growth, and product performance. The content is structured as a presentation with charts and highlights, typical of investor presentations. It is not a full annual or quarterly report, nor an earnings release summary. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement or certification. Therefore, the document fits the category of an Investor Presentation (IP).
2019-11-13 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investors Presentation (Q2'FY20), November, 2019' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter and half-year ended 30th September 2019, including revenue, profit, segment-wise growth, and product performance. The content is structured as a presentation with charts and highlights, typical of investor presentations. It is not a full annual or interim report, nor is it an earnings release which would be shorter and more summary-focused. It is not an announcement of a report publication but the actual presentation document itself. Therefore, the document fits the category of an Investor Presentation (IP).
2019-11-13 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 13, 2019, reporting Morepen Laboratories Limited's financial performance for the quarter and half-year ended September 30, 2019. It contains detailed financial data including net sales revenue, EBITDA, net profit before and after tax, segment-wise sales, and growth percentages. The document is about the company's financial results for a specific interim period (Q2 and H1 FY 2019-20). It is not a full annual report, nor is it a brief earnings highlight or a transcript. It is a comprehensive financial update for a period shorter than a full fiscal year, with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2019-11-13 English
Morepen Labs catches Pharma sector uptrend in Q1 FY 2019-20. Company's Net Profit rises by a whopping 256 percent led by a significant jump in its APIs exports.
Earnings Release Classification · 95% confidence The document is a press release dated November 13, 2019, reporting Morepen Laboratories' financial performance for the quarter and half-year ended September 30, 2019. It contains detailed financial figures such as net sales revenue, EBITDA, net profit before and after tax, segment-wise sales growth, and business highlights. The document is not a full annual or interim report but a public announcement of financial results with key metrics and business updates. It is not a transcript, audit report, or management discussion but a press release summarizing financial performance. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. The document length (15,000 characters) and content confirm it is a full press release, not just a brief announcement or a report publication notice.
2019-11-13 English
Financial Result Updates
Regulatory Filings
2019-11-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.